MedTrace Logo

Adjuvant Capecitabine in Elderly Patients With Breast Cancer: a Phase II Study

NCT00263705 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 43

Last updated 2011-02-24

No results posted yet for this study

Summary

Determination of guidelines regarding the use of adjuvant chemotherapy for early breast cancer in this population of Patients over 70 years old.

Conditions

Interventions

DRUG

Adjuvant capecitabine

Capecitabine 2000 mg/m² daily six cycles

DRUG

capecitabine in aduvant setting

capecitabine in aduvant setting in ederly with breast cancer

Sponsors & Collaborators

  • Jules Bordet Institute

    lead OTHER

Principal Investigators

  • Chantal Bernard, MD · Jules Bordet Institute

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
70 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-01-31
Primary Completion
2009-08-31
Completion
2009-08-31

Countries

  • Belgium

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00263705 on ClinicalTrials.gov